Medinex Ltd. (OTX) AI Stock Analysis

• Market Cap: S$32.29M
• Dividend Yield: 7.3%
• Average Volume (3M): 102.58K
• Price to Earnings (P/E): 9.0
• Beta (1Y): -0.10
• Revenue Growth: -2.08%
• EPS Growth: 129.31%
• Country: SG
• Employees: 73
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Care Facilities
• EPS (TTM): 0.02
• Shares Outstanding: 134,543,840
• 10 Day Avg. Volume: 45,910
• 30 Day Avg. Volume: 102,580
• PEG Ratio: 0.05
• Price to Book (P/B): 1.57
• Price to Sales (P/S): 2.05
• P/FCF Ratio: 7.90
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 80 Outperform
• Price Target: S$0.50 ▲(108.33% Upside)

Medinex Ltd. demonstrates strong financial performance with robust growth and profitability, supported by a stable balance sheet and strong cash flow generation. The technical analysis indicates positive momentum, although caution is advised due to the Stochastic indicator. The valuation is attractive with a low P/E ratio and high dividend yield, making it appealing for value and income investors.

Positive Factors

Revenue Growth

The consistent revenue growth reflects the company's expanding market presence and successful product adoption, supporting long-term business sustainability.

Cash Generation

Strong cash generation enhances financial flexibility, allowing for reinvestment in innovation and expansion, crucial for sustaining competitive advantage.

Profitability

High profitability margins indicate efficient cost management and operational efficiency, supporting long-term financial health and shareholder value.

Negative Factors

Market Saturation Risk

Operating in a niche market could limit growth opportunities if market saturation occurs, potentially impacting long-term revenue expansion.

Employee Base

A relatively small workforce may limit the company's ability to scale operations quickly, potentially hindering its ability to capitalize on growth opportunities.

Dependence on Partnerships

Heavy reliance on partnerships for growth could pose risks if these alliances weaken, affecting product development and market expansion efforts.

Medinex Ltd. Business Overview & Revenue Model

Company Description

Medinex Limited, an investment holding company, provides professional support services to medical clinics in Singapore. It operates through four segments: Medical Support Services, Business Support Services, Pharmaceutical Services, and Medical Services. The company engages in the setting up of clinics, facilitating applications for relevant clinic licenses, value added services to healthcare sectors, turnkey solutions, as well as strategic advice to general practitioners and specialists on establishing clinic facilities. It also provides accounting and tax agent, human resource management, and corporate secretarial services, as well as business support services, such as accounting, tax agent, human resource management, and corporate secretarial services to various sectors, such as food and beverage, retail, education, and beauty. In addition, the company procures medical and pharmaceutical products to clinics. Further, the company offers diagnostic and x-rays, pre-employment check-ups, vaccination, customized healthcare plans, and health screening services in clinics. Additionally, it provides advisory services, and business and management consultancy services, call support services, and data protection officer services to its customers; and training services. Medinex Limited was incorporated in 2009 and is headquartered in Singapore.

How the Company Makes Money

Medinex Ltd. generates revenue through multiple streams, primarily from the sale of its medical devices and software solutions to hospitals, clinics, and healthcare providers. The company also earns income through subscription-based models for its software services, which provide ongoing support and updates to clients. Additionally, Medinex Ltd. has established significant partnerships with healthcare organizations and technology firms, enabling collaborative product development and market expansion. Licensing agreements and revenue-sharing arrangements with third-party developers further contribute to its earnings. The company’s focus on research and innovation allows it to stay competitive and create demand for its products, ultimately driving sales and revenue growth.

Medinex Ltd. Financial Statement Overview

Summary

Medinex Ltd. exhibits strong financial health across all verticals. The income statement shows robust growth and profitability, the balance sheet reflects financial stability with low leverage, and the cash flow statement indicates strong cash generation and liquidity. The company is well-positioned for future growth with a solid financial foundation.

Income Statement

Medinex Ltd. has demonstrated strong revenue growth with a 14.5% increase in the latest year, supported by a high gross profit margin of 77.48%. The company also maintains a healthy net profit margin of 22.12%, indicating efficient cost management. EBIT and EBITDA margins are robust at 23.64% and 27.96%, respectively, showcasing operational efficiency. Overall, the income statement reflects a positive growth trajectory and strong profitability.

Balance Sheet

The balance sheet of Medinex Ltd. shows a solid financial position with a low debt-to-equity ratio of 0.10, indicating low leverage and financial stability. Return on equity stands at 16.95%, reflecting effective utilization of shareholder funds. The equity ratio is strong, suggesting a well-capitalized structure. Overall, the balance sheet is stable with low financial risk.

Cash Flow

Medinex Ltd. has achieved a significant free cash flow growth rate of 236.8%, indicating strong cash generation capabilities. The operating cash flow to net income ratio is 1.04, suggesting efficient conversion of income into cash. The free cash flow to net income ratio is nearly 1, highlighting effective cash management. Overall, the cash flow statement reflects strong liquidity and cash generation.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	12.82M	12.81M	12.58M	12.97M	11.99M	10.79M
Gross Profit	4.73M	9.93M	9.68M	9.48M	8.57M	3.31M
EBITDA	2.89M	3.58M	1.79M	2.88M	4.00M	1.69M
Net Income	2.83M	2.83M	1.03M	1.70M	2.81M	3.49M
Balance Sheet
Total Assets	20.69M	20.69M	20.50M	22.59M	22.98M	23.43M
Cash, Cash Equivalents and Short-Term Investments	5.56M	5.56M	5.17M	4.15M	6.34M	6.73M
Total Debt	1.67M	1.67M	2.08M	2.34M	3.10M	3.95M
Total Liabilities	3.96M	3.96M	4.34M	4.81M	5.51M	6.50M
Stockholders Equity	16.72M	16.72M	16.12M	17.57M	17.25M	16.66M
Cash Flow
Free Cash Flow	3.33M	3.33M	2.67M	2.83M	2.63M	2.96M
Operating Cash Flow	3.35M	3.35M	2.70M	3.03M	2.86M	3.04M
Investing Cash Flow	99.11K	243.45K	1.66M	-2.19M	-16.91K	-2.61M
Financing Cash Flow	-4.79M	-3.20M	-3.33M	-3.02M	-3.16M	748.53K

Medinex Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.24
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SG:OTX, the sentiment is Positive. The current price of 0.24 is above the 20-day moving average (MA) of 0.24, above the 50-day MA of 0.24, and above the 200-day MA of 0.21, indicating a bullish trend. The MACD of <0.01 indicates Positive momentum. The RSI at 56.90 is Neutral, neither overbought nor oversold. The STOCH value of 66.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SG:OTX.

Medinex Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
OTX	80 Outperform	S$32.29M	9.02	20.77%	7.30%	-2.08%	129.31%
1B1	67 Neutral	S$55.37M	6.56	47.36%	3.37%	1.58%	115.29%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Medinex Ltd. Corporate Events

Medinex Completes Acquisition of Carlin Management Services

Medinex Limited has completed the acquisition of Carlin Management Services Pte. Ltd. by issuing 1,852,667 new ordinary shares and transferring 814,000 treasury shares to the seller. This transaction increases Medinex’s total issued shares to 134,543,843, with the new shares expected to be listed on December 15, 2025.

The most recent analyst rating on (SG:OTX) stock is a Buy with a S$0.50 price target. To see the full list of analyst forecasts on Medinex Ltd. stock, see the SG:OTX Stock Forecast page.

Medinex Ltd. Completes Acquisition Consideration with Treasury Share Transfer

Medinex Ltd., a company incorporated in Singapore, has announced the transfer of 814,000 treasury shares to Lee Lay Lian as part of the consideration for the acquisition of Carlin Management Services Pte. Ltd. This transfer marks the full satisfaction of the acquisition consideration, reducing the company’s treasury shares to zero and potentially impacting its share capital structure.

The most recent analyst rating on (SG:OTX) stock is a Buy with a S$0.50 price target. To see the full list of analyst forecasts on Medinex Ltd. stock, see the SG:OTX Stock Forecast page.

Medinex Ltd. Expands with Carlin Management Acquisition

Medinex Ltd., incorporated in Singapore, has announced the issuance of 2,666,667 consideration shares to Lee Lay Lian as part of the acquisition of Carlin Management Services Pte. Ltd. The company has received approval from the Singapore Exchange Securities Trading Limited for the listing of 1,852,667 of these shares on the Catalist board, subject to compliance with listing requirements. This move signifies Medinex’s strategic expansion and fulfillment of acquisition agreements, potentially impacting its market positioning and stakeholder interests.

The most recent analyst rating on (SG:OTX) stock is a Buy with a S$0.50 price target. To see the full list of analyst forecasts on Medinex Ltd. stock, see the SG:OTX Stock Forecast page.